Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c

Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 8, 2022 4:05 PM EDT

Received U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA target action date of November 26, 2022Achieved $15.7 million in Q2 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesDosed first patient in Phase 3 VALIANT study in IC-MPGN and C3GCash and investments of $852.8 million as of June 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) --... More